Exenatide Synthetic Patent Expiration
Exenatide Synthetic is used for improving glycemic control in patients with Type 2 diabetes, reducing food intake, delaying gastric motility, reducing body weight, and stimulating insulin release. It was first introduced by Astrazeneca Ab
Exenatide Synthetic Patents
Given below is the list of patents protecting Exenatide Synthetic, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bydureon Bcise |
US8895033 (Pediatric) | Sustained release formulations using non-aqueous carriers | Apr 04, 2031 | Astrazeneca Ab |
| Bydureon Bcise | US8895033 | Sustained release formulations using non-aqueous carriers | Oct 04, 2030 | Astrazeneca Ab |
| Bydureon Pen |
US8721615 (Pediatric) | Ampoule comprising an ampoule holder | Jul 18, 2030 | Astrazeneca Ab |
| Bydureon Pen |
US8998876 (Pediatric) | Ampoule comprising an ampoule holder | Jul 07, 2030 | Astrazeneca Ab |
| Bydureon | US8685934 | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof | May 26, 2030 | Astrazeneca Ab |
| Bydureon Pen | US8685934 | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof | May 26, 2030 | Astrazeneca Ab |
| Bydureon Pen | US8721615 | Ampoule comprising an ampoule holder | Jan 18, 2030 | Astrazeneca Ab |
| Bydureon Pen | US8998876 | Ampoule comprising an ampoule holder | Jan 07, 2030 | Astrazeneca Ab |
| Bydureon | US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same | Dec 16, 2029 | Astrazeneca Ab |
| Bydureon Pen | US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same | Dec 16, 2029 | Astrazeneca Ab |
| Bydureon Pen |
US8690837 (Pediatric) | Mixing device for a two-chamber ampoule | Nov 19, 2029 | Astrazeneca Ab |
| Bydureon Pen |
US8827963 (Pediatric) | Administering device with holding mechanism | Aug 04, 2029 | Astrazeneca Ab |
| Bydureon Pen | US8690837 | Mixing device for a two-chamber ampoule | May 19, 2029 | Astrazeneca Ab |
| Bydureon Pen | US8827963 | Administering device with holding mechanism | Feb 04, 2029 | Astrazeneca Ab |
| Bydureon Pen |
US8439864 (Pediatric) | Device for administering fluid from a multi-chamber ampoule in incremental steps | Sep 25, 2028 | Astrazeneca Ab |
| Bydureon Pen |
US9320853 (Pediatric) | Method for administering a fluid active substance from a multi-chamber ampoule | Sep 25, 2028 | Astrazeneca Ab |
| Bydureon |
US8361972 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor | Sep 21, 2028 | Astrazeneca Ab |
| Bydureon Bcise |
US8361972 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor | Sep 21, 2028 | Astrazeneca Ab |
| Bydureon Pen |
US8361972 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor | Sep 21, 2028 | Astrazeneca Ab |
| Bydureon | US7851502 | Pharmaceutical formulations containing an SGLT2 inhibitor | Aug 19, 2028 | Astrazeneca Ab |
| Bydureon Pen | US7851502 | Pharmaceutical formulations containing an SGLT2 inhibitor | Aug 19, 2028 | Astrazeneca Ab |
| Bydureon Pen |
US8216180 (Pediatric) | Administering apparatus with functional drive element | Jul 12, 2028 | Astrazeneca Ab |
| Bydureon Pen |
US8758292 (Pediatric) | Administering apparatus with functional drive element | May 12, 2028 | Astrazeneca Ab |
| Bydureon | US8439864 | Device for administering fluid from a multi-chamber ampoule in incremental steps | Mar 25, 2028 | Astrazeneca Ab |
| Bydureon Pen | US8439864 | Device for administering fluid from a multi-chamber ampoule in incremental steps | Mar 25, 2028 | Astrazeneca Ab |
| Bydureon Pen | US9320853 | Method for administering a fluid active substance from a multi-chamber ampoule | Mar 25, 2028 | Astrazeneca Ab |
| Bydureon | US8221786 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Bydureon | US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Bydureon | US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Bydureon Bcise | US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Bydureon Pen | US8221786 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Bydureon Pen | US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Bydureon Pen | US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Bydureon | US8216180 | Administering apparatus with functional drive element | Jan 12, 2028 | Astrazeneca Ab |
| Bydureon Pen | US8216180 | Administering apparatus with functional drive element | Jan 12, 2028 | Astrazeneca Ab |
| Bydureon |
US8501698 (Pediatric) | Crystal structures of SGLT2 inhibitors and processes for preparing same | Dec 20, 2027 | Astrazeneca Ab |
| Bydureon Bcise |
US8501698 (Pediatric) | Crystal structures of SGLT2 inhibitors and processes for preparing same | Dec 20, 2027 | Astrazeneca Ab |
| Bydureon Pen |
US8501698 (Pediatric) | Crystal structures of SGLT2 inhibitors and processes for preparing same | Dec 20, 2027 | Astrazeneca Ab |
| Bydureon Pen | US8758292 | Administering apparatus with functional drive element | Nov 12, 2027 | Astrazeneca Ab |
| Bydureon | US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same | Jun 20, 2027 | Astrazeneca Ab |
| Bydureon Bcise | US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same | Jun 20, 2027 | Astrazeneca Ab |
| Bydureon Pen | US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same | Jun 20, 2027 | Astrazeneca Ab |
| Bydureon |
US8329648 (Pediatric) | Methods for treating diabetes and reducing body weight | Feb 18, 2027 | Astrazeneca Ab |
| Bydureon |
US8906851 (Pediatric) | Method for treating diabetes | Feb 18, 2027 | Astrazeneca Ab |
| Bydureon |
US9884092 (Pediatric) | Methods for treating diabetes and reducing body weight | Feb 18, 2027 | Astrazeneca Ab |
| Bydureon Bcise |
US8329648 (Pediatric) | Methods for treating diabetes and reducing body weight | Feb 18, 2027 | Astrazeneca Ab |
| Bydureon Bcise |
US8906851 (Pediatric) | Method for treating diabetes | Feb 18, 2027 | Astrazeneca Ab |
| Bydureon Bcise |
US9884092 (Pediatric) | Methods for treating diabetes and reducing body weight | Feb 18, 2027 | Astrazeneca Ab |
| Bydureon Pen |
US8329648 (Pediatric) | Methods for treating diabetes and reducing body weight | Feb 18, 2027 | Astrazeneca Ab |
| Bydureon Pen |
US8906851 (Pediatric) | Method for treating diabetes | Feb 18, 2027 | Astrazeneca Ab |
| Bydureon Pen |
US9884092 (Pediatric) | Methods for treating diabetes and reducing body weight | Feb 18, 2027 | Astrazeneca Ab |
| Bydureon | US8329648 | Methods for treating diabetes and reducing body weight | Aug 18, 2026 | Astrazeneca Ab |
| Bydureon | US8906851 | Method for treating diabetes | Aug 18, 2026 | Astrazeneca Ab |
| Bydureon | US9884092 | Methods for treating diabetes and reducing body weight | Aug 18, 2026 | Astrazeneca Ab |
| Bydureon Bcise | US8329648 | Methods for treating diabetes and reducing body weight | Aug 18, 2026 | Astrazeneca Ab |
| Bydureon Bcise | US8906851 | Method for treating diabetes | Aug 18, 2026 | Astrazeneca Ab |
| Bydureon Bcise | US9884092 | Methods for treating diabetes and reducing body weight | Aug 18, 2026 | Astrazeneca Ab |
| Bydureon Pen | US8329648 | Methods for treating diabetes and reducing body weight | Aug 18, 2026 | Astrazeneca Ab |
| Bydureon Pen | US8906851 | Method for treating diabetes | Aug 18, 2026 | Astrazeneca Ab |
| Bydureon Pen | US9884092 | Methods for treating diabetes and reducing body weight | Aug 18, 2026 | Astrazeneca Ab |
| Bydureon |
US6515117 (Pediatric) | C-aryl glucoside SGLT2 inhibitors and method | Apr 04, 2026 | Astrazeneca Ab |
| Bydureon Bcise |
US6515117 (Pediatric) | C-aryl glucoside SGLT2 inhibitors and method | Apr 04, 2026 | Astrazeneca Ab |
| Bydureon Pen |
US6515117 (Pediatric) | C-aryl glucoside SGLT2 inhibitors and method | Apr 04, 2026 | Astrazeneca Ab |
| Bydureon |
US7456254 (Pediatric) | Polymer-based sustained release device | Dec 30, 2025 | Astrazeneca Ab |
| Bydureon Bcise |
US7456254 (Pediatric) | Polymer-based sustained release device | Dec 30, 2025 | Astrazeneca Ab |
| Bydureon Pen |
US7456254 (Pediatric) | Polymer-based sustained release device | Dec 30, 2025 | Astrazeneca Ab |
| Bydureon |
US7612176 (Pediatric) | Polymer-based sustained release device | Oct 13, 2025 | Astrazeneca Ab |
| Bydureon |
US8431685 (Pediatric) | Polymer-based sustained release device | Oct 13, 2025 | Astrazeneca Ab |
| Bydureon |
US8461105 (Pediatric) | Polymer-based sustained release device | Oct 13, 2025 | Astrazeneca Ab |
| Bydureon Bcise |
US7612176 (Pediatric) | Polymer-based sustained release device | Oct 13, 2025 | Astrazeneca Ab |
| Bydureon Bcise |
US8431685 (Pediatric) | Polymer-based sustained release device | Oct 13, 2025 | Astrazeneca Ab |
| Bydureon Bcise |
US8461105 (Pediatric) | Polymer-based sustained release device | Oct 13, 2025 | Astrazeneca Ab |
| Bydureon Pen |
US7612176 (Pediatric) | Polymer-based sustained release device | Oct 13, 2025 | Astrazeneca Ab |
| Bydureon Pen |
US8431685 (Pediatric) | Polymer-based sustained release device | Oct 13, 2025 | Astrazeneca Ab |
| Bydureon Pen |
US8461105 (Pediatric) | Polymer-based sustained release device | Oct 13, 2025 | Astrazeneca Ab |
| Bydureon | US6515117 | C-aryl glucoside SGLT2 inhibitors and method | Oct 04, 2025 | Astrazeneca Ab |
| Bydureon Bcise | US6515117 | C-aryl glucoside SGLT2 inhibitors and method | Oct 04, 2025 | Astrazeneca Ab |
| Bydureon Pen | US6515117 | C-aryl glucoside SGLT2 inhibitors and method | Oct 04, 2025 | Astrazeneca Ab |
| Bydureon | US7456254 | Polymer-based sustained release device |
Jun 30, 2025
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US7456254 | Polymer-based sustained release device |
Jun 30, 2025
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US7456254 | Polymer-based sustained release device |
Jun 30, 2025
(Expired) | Astrazeneca Ab |
| Bydureon | US7612176 | Polymer-based sustained release device |
Apr 13, 2025
(Expired) | Astrazeneca Ab |
| Bydureon | US8431685 | Polymer-based sustained release device |
Apr 13, 2025
(Expired) | Astrazeneca Ab |
| Bydureon | US8461105 | Polymer-based sustained release device |
Apr 13, 2025
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US7612176 | Polymer-based sustained release device |
Apr 13, 2025
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US8431685 | Polymer-based sustained release device |
Apr 13, 2025
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US8461105 | Polymer-based sustained release device |
Apr 13, 2025
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US7612176 | Polymer-based sustained release device |
Apr 13, 2025
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US8431685 | Polymer-based sustained release device |
Apr 13, 2025
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US8461105 | Polymer-based sustained release device |
Apr 13, 2025
(Expired) | Astrazeneca Ab |
| Bydureon |
US7563871 (Pediatric) | Polymer-based sustained release device |
Oct 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon |
US9238076 (Pediatric) | Polymer-based sustained release device |
Oct 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon Bcise |
US7563871 (Pediatric) | Polymer-based sustained release device |
Oct 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon Bcise |
US9238076 (Pediatric) | Polymer-based sustained release device |
Oct 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon Pen |
US7563871 (Pediatric) | Polymer-based sustained release device |
Oct 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon Pen |
US9238076 (Pediatric) | Polymer-based sustained release device |
Oct 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon | US7563871 | Polymer-based sustained release device |
Apr 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon | US9238076 | Polymer-based sustained release device |
Apr 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US7563871 | Polymer-based sustained release device |
Apr 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US9238076 | Polymer-based sustained release device |
Apr 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US7563871 | Polymer-based sustained release device |
Apr 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US9238076 | Polymer-based sustained release device |
Apr 15, 2024
(Expired) | Astrazeneca Ab |
| Bydureon |
US6824822 (Pediatric) | Residual solvent extraction method and microparticles produced thereby |
Apr 09, 2023
(Expired) | Astrazeneca Ab |
| Bydureon Bcise |
US6824822 (Pediatric) | Residual solvent extraction method and microparticles produced thereby |
Apr 09, 2023
(Expired) | Astrazeneca Ab |
| Bydureon Pen |
US6824822 (Pediatric) | Residual solvent extraction method and microparticles produced thereby |
Apr 09, 2023
(Expired) | Astrazeneca Ab |
| Bydureon | US6824822 | Residual solvent extraction method and microparticles produced thereby |
Oct 09, 2022
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US6824822 | Residual solvent extraction method and microparticles produced thereby |
Oct 09, 2022
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US6824822 | Residual solvent extraction method and microparticles produced thereby |
Oct 09, 2022
(Expired) | Astrazeneca Ab |
| Bydureon |
US7223440 (Pediatric) | Residual solvent extraction method and microparticles produced thereby |
Mar 03, 2022
(Expired) | Astrazeneca Ab |
| Bydureon Bcise |
US7223440 (Pediatric) | Residual solvent extraction method and microparticles produced thereby |
Mar 03, 2022
(Expired) | Astrazeneca Ab |
| Bydureon Pen |
US7223440 (Pediatric) | Residual solvent extraction method and microparticles produced thereby |
Mar 03, 2022
(Expired) | Astrazeneca Ab |
| Bydureon | US7223440 | Residual solvent extraction method and microparticles produced thereby |
Aug 31, 2021
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US7223440 | Residual solvent extraction method and microparticles produced thereby |
Aug 31, 2021
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US7223440 | Residual solvent extraction method and microparticles produced thereby |
Aug 31, 2021
(Expired) | Astrazeneca Ab |
| Bydureon | US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Bydureon | US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Bydureon | US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Bydureon | US6479065 | Process for the preparation of polymer-based sustained release compositions |
Aug 10, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US6479065 | Process for the preparation of polymer-based sustained release compositions |
Aug 10, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US6479065 | Process for the preparation of polymer-based sustained release compositions |
Aug 10, 2020
(Expired) | Astrazeneca Ab |
| Bydureon | US6495164 | Preparation of injectable suspensions having improved injectability |
May 25, 2020
(Expired) | Astrazeneca Ab |
| Bydureon | US6667061 | Preparation of injectable suspensions having improved injectability |
May 25, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US6667061 | Preparation of injectable suspensions having improved injectability |
May 25, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US6495164 | Preparation of injectable suspensions having improved injectability |
May 25, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US6667061 | Preparation of injectable suspensions having improved injectability |
May 25, 2020
(Expired) | Astrazeneca Ab |
| Bydureon | US6872700 | Methods for glucagon suppression |
Jan 14, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US6872700 | Methods for glucagon suppression |
Jan 14, 2020
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US6872700 | Methods for glucagon suppression |
Jan 14, 2020
(Expired) | Astrazeneca Ab |
| Byetta | US6872700 | Methods for glucagon suppression |
Jan 14, 2020
(Expired) | Astrazeneca Ab |
| Byetta | US6902744 | Exendin agonist formulations and methods of administration thereof |
Jan 14, 2020
(Expired) | Astrazeneca Ab |
| Bydureon | US6956026 | Use of exendins for the reduction of food intake |
Jan 07, 2018
(Expired) | Astrazeneca Ab |
| Bydureon | US7741269 | Exendins and exendin agonists for weight reduction and obesity |
Jan 07, 2018
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US6956026 | Use of exendins for the reduction of food intake |
Jan 07, 2018
(Expired) | Astrazeneca Ab |
| Bydureon Bcise | US7741269 | Exendins and exendin agonists for weight reduction and obesity |
Jan 07, 2018
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US6956026 | Use of exendins for the reduction of food intake |
Jan 07, 2018
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US7741269 | Exendins and exendin agonists for weight reduction and obesity |
Jan 07, 2018
(Expired) | Astrazeneca Ab |
| Byetta | US6956026 | Use of exendins for the reduction of food intake |
Jan 07, 2018
(Expired) | Astrazeneca Ab |
| Byetta | US7741269 | Exendins and exendin agonists for weight reduction and obesity |
Jan 07, 2018
(Expired) | Astrazeneca Ab |
| Byetta | US7297761 | Pharmaceutical compositions containing exendins |
Oct 15, 2017
(Expired) | Astrazeneca Ab |
| Byetta | US7521423 | Exendin pharmaceutical compositions |
Oct 15, 2017
(Expired) | Astrazeneca Ab |
| Bydureon | US6858576 | Methods for regulating gastrointestinal motility |
Jan 06, 2017
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US6858576 | Methods for regulating gastrointestinal motility |
Jan 06, 2017
(Expired) | Astrazeneca Ab |
| Byetta | US6858576 | Methods for regulating gastrointestinal motility |
Jan 06, 2017
(Expired) | Astrazeneca Ab |
| Bydureon | US5424286 | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
Dec 01, 2016
(Expired) | Astrazeneca Ab |
| Bydureon Pen | US5424286 | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
Dec 01, 2016
(Expired) | Astrazeneca Ab |
| Byetta | US5424286 | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
Dec 01, 2016
(Expired) | Astrazeneca Ab |
Exenatide Synthetic's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Exenatide Synthetic Generic API Manufacturers
Several generic applications have been filed for Exenatide Synthetic.
Given below is the list of companies who have filed for Exenatide Synthetic generic, along with the locations of their manufacturing plants worldwide.
1. AMNEAL
Amneal Eu Ltd has filed for 2 different strengths of generic version for Exenatide Synthetic. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MCG/1.2ML (250MCG/ML)
(reference standard) | injectable | Prescription | SUBCUTANEOUS | N/A | Nov 19, 2024 |
| 600MCG/2.4ML (250MCG/ML)
(reference standard) | injectable | Prescription | SUBCUTANEOUS | N/A | Nov 19, 2024 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||